Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly breaks off sepsis deal

This article was originally published in Clinica

Executive Summary

Eli Lilly has told point-of-care diagnostics company PharmaNetics that it is terminating their two-year old agreement to develop a sepsis monitoring test. Lilly has cited the test's failure to provide results across a wide therapeutic range "with the precision originally specified in the marketing characteristics established at the inception of the project". PharmaNetics claims that there is no known method capable of meeting all the originally targeted specifications.

Topics

UsernamePublicRestriction

Register

MT079023

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel